Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study

Qianfoshan Hospital

Status: Enrolling

Conditions: Arterial Pulmonary Hypertension (PAH)

Treatments: Drug: Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs

Study type: Observational

Funder types: Other

Identifiers

NCT06753981

YXLL-KY-2024 (124)

Details and patient eligibility

About

This study is a multicenter, prospective, observational study aimed at investigating the efficacy and safety of triple targeted drug therapy in patients with arterial pulmonary hypertension (PAH) who are not at low risk and are receiving initial treatment. The prognosis of arterial pulmonary hypertension is explored.

Enrollment: 48 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Consent and sign the informed consent form
• Non-low-risk PAH treatment-naive patients

Exclusion criteria

• Positive acute vascular response test for idiopathic/hereditary/drug-related arterial pulmonary hypertension
• Pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) with arterial pulmonary
• Pregnant or lactating women
• Suffering from mental illness or cognitive impairment
• PAH patients with concurrent malignant tumors
• Patients with moderate to severe hepatic impairment, renal impairment, and severe anemia
• Currently participating in other interventional clinical studies
• Key clinical data is incomplete, or the investigator considers that the patient has other factors that make them unsuitable for this study.

Trial design

48 participants in 1 patient group

Non-low-risk PAH treatment-naive patients

Treatment:

Drug: Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs